Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program
Source: View publication →
A multicenter randomized controlled trial demonstrating that a virtual sustained tobacco treatment program consisting of telehealth counseling and nicotine replacement therapy significantly increased 6-month smoking quit rates compared to standard quitline referral among recently diagnosed cancer patients in community oncology settings.
Key Findings
Study Design
Study Limitations
Clinical Significance
The Smokefree Support Study 2.0 demonstrates that integrating virtual, sustained counseling alongside free nicotine replacement therapy into community oncology settings is both practical and highly efficacious. This scalable telehealth framework addresses a critical gap in comprehensive cancer care, offering a robust, evidence-based model to deliver necessary tobacco cessation support to high-risk patients directly in their communities, regardless of geographic barriers.
Historical Context
Continuing to smoke following a cancer diagnosis is strongly associated with increased treatment toxicities, higher risks of secondary malignancies, diminished therapeutic efficacy, and decreased overall survival. Recognizing this, initiatives like the NCI Cancer Center Cessation Initiative (C3I) and the American College of Surgeons Commission on Cancer established standards for universal tobacco screening and treatment. However, the robust integration of these cessation services historically lagged in community oncology practices where the majority of patients in the US receive care. Building upon earlier efficacy studies of intensive behavioral counseling, the EAQ171CD trial was designed to bridge this implementation gap by testing a proactive, telehealth-based model uniquely optimized for scalability across the national community-based NCORP network.
Guided Discussion
High-yield insights from every perspective
How does continued tobacco use pathophysiologically impact the efficacy and toxicity of systemic cancer therapies, and why does this make intensive cessation interventions critical for patients recently diagnosed with cancer?
Key Response
Continued smoking can induce hepatic CYP450 enzymes (e.g., CYP1A2), increasing the clearance of certain chemotherapeutics like erlotinib or irinotecan, thereby reducing their efficacy. It also increases tissue hypoxia which reduces the efficacy of radiotherapy, and exacerbates pulmonary, wound healing, and cardiovascular toxicities, underscoring the urgent need for cessation at diagnosis.
When initiating Nicotine Replacement Therapy (NRT) in a newly diagnosed cancer patient who smokes 1.5 packs per day, what is the optimal initial NRT strategy according to current best practices, and how does the virtual counseling component complement this medical management?
Key Response
Evidence supports combination NRT (a long-acting patch for baseline craving control plus a short-acting form like gum or lozenge for breakthrough cravings) rather than monotherapy. Virtual counseling complements this by improving adherence to the NRT regimen, managing side effects in real-time, and addressing behavioral triggers, overcoming the notoriously low adherence rates seen with standard quitline referrals.
Given that cancer patients often face overwhelming treatment burdens and frequent clinic visits, how does a virtual, sustained tobacco treatment model mitigate the 'competing demands' barrier commonly seen in oncology practices compared to standard proactive quitline referrals?
Key Response
Standard quitlines often fail in oncology because they operate in a silo, requiring patients to coordinate extra care during an overwhelming cancer diagnosis. A sustained, integrated virtual model proactively delivers continuous behavioral support and medication management without adding travel burden, effectively integrating cessation into the longitudinal continuum of cancer care.
If we adopt the ECOG-ACRIN EAQ171CD virtual sustained model in our community oncology practice, what structural changes are required to shift our current 'ask and advise' workflow to an 'opt-out' integrated virtual treatment model, and what are the clinical workflow implications?
Key Response
Shifting from standard quitline referral to integrated virtual sustained treatment requires EHR integration for automatic referrals (opt-out), establishing telehealth workflows for counseling, and ensuring dedicated staff can manage longitudinal NRT prescribing and follow-up without disrupting standard oncology workflows. It requires viewing cessation as a concurrent cancer treatment rather than a primary care preventive measure.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
In evaluating the ECOG-ACRIN EAQ171CD trial, how does the choice of standard quitline referral as an active control, rather than standard-of-care 'usual practice', impact the interpretation of the effect size, and what statistical methods are necessary to account for cluster effects in community oncology (NCORP) settings?
Key Response
Using an active control (quitline) instead of 'usual care' (often just brief advice) sets a higher bar for superiority, meaning the observed effect size is likely a conservative estimate of real-world benefit. Furthermore, as a multicenter NCORP study, mixed-effects models or generalized estimating equations (GEE) are essential to account for intra-cluster correlation among patients treated at the same community site.
As a peer reviewer, how would you critically evaluate the study's reliance on self-reported 6-month quit rates versus biochemically verified abstinence, particularly in a population of recently diagnosed cancer patients where social desirability bias might be exceptionally high?
Key Response
A rigorous reviewer would flag that cancer patients may underreport smoking due to stigma or fear of judgment from their oncologists (social desirability bias). While biochemical verification (e.g., cotinine, exhaled CO) is the gold standard, it is logistically challenging in a virtual, multicenter community trial. The study must adequately address whether the magnitude of the difference between arms could be entirely explained by differential misclassification.
How should the findings of the EAQ171CD trial influence the next iteration of ASCO and NCCN guidelines regarding the recommended standard of care for tobacco cessation delivery in community oncology, and does this evidence upgrade the strength of recommendation for telehealth-based continuous interventions?
Key Response
Current NCCN guidelines strongly recommend combination pharmacotherapy and behavioral counseling, but practical implementation remains poor. This RCT provides Level 1 evidence that virtual, sustained, integrated treatment outperforms standard quitlines. The committee should consider upgrading recommendations to explicitly advocate for dedicated virtual longitudinal cessation programs over passive quitline referrals as the preferred care delivery model in community oncology settings.
Clinical Landscape
Noteworthy Related Trials
Sustained Care Smoking Cessation Trial
Tested
Sustained care via automated interactive voice response calls and medication
Population
Hospitalized daily smokers
Comparator
Standard care (in-hospital counseling only)
Endpoint
Biochemically validated tobacco abstinence at 6 months
EAGLES Trial
Tested
Varenicline or bupropion
Population
Smokers with and without psychiatric disorders
Comparator
Nicotine patch or placebo
Endpoint
Continuous abstinence for weeks 9-12
CATCH Trial
Tested
Longitudinal tobacco treatment integrating counseling and medication
Population
Recently diagnosed cancer patients who smoke
Comparator
Usual care
Endpoint
Biochemically validated 7-day abstinence at 6 months
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis